Unfortunately, space does not permit an examination of each of the examples he cites, so I will focus on several facets of melancholia to illustrate the errors in his argument. Dr Shorter states that melancholia is "the most solid disease" 1, p 59 found in psychiatry, noting the response to the dexamethasone suppression test (DST), and a distinctive response to tricyclic antidepressants and electroconvulsive therapy (ECT). Yet in 1989, Zimmerman and Spitzer 2 cited 12 studies that showed no evidence of a preferential response to somatic therapies in melancholia. Peselow et al 3 found similar results in 1992. The DST has fared no better, with a meta-analysis in 1997 4 finding no differences in melancholia, compared with nonmelancholic depression. More recently, other authors 5 concluded that the DST is probably not suitable as a biologic marker for depressive subtypes. Clearly, there are major problems with the DST in terms of sensitivity and specificity that Dr Shorter ignores.
Moving beyond the arguments posed by Dr Shorter and Dr van Praag, there is another development that seems to pose a greater threat to the paradigm of disease and drug specificity. I refer to the growing approval of multiple drugs for the treatment of the same disorder, although the drugs have little in common with regard to their alleged mechanisms of action. For example, mania can be treated with antipsychotics, lithium, divalproex, carbamazepine, ECT, and lamotrigene. Major depression can be treated with ECT, antidepressants, several atypical antipsychotics, vagus nerve stimulation, cognitive-behavioural therapy, and transcranial magnetic stimulation. On the other hand, sertraline can be used in the treatment of major depression, posttraumatic stress disorder, panic, generalized anxiety disorder, obsessive-compulsive disorder, and premenstrual dysphoria.
These developments in psychopharmacology are interesting from any number of perspectives, but most importantly seem to argue strongly against the specificity of drug or disease. I submit that from the clinician's viewpoint, we are already using a dimensional approach, whether we acknowledge it or not. 
Charles E Dean, MD Minneapolis, Minnesota

REPLIES
Disease Versus Dimension in Diagnosis
Dear Editor:
In my discussion with Dr Shorter, I argued against the nosological model in psychiatric diagnosing. Obviously Dr Dean is on my side.
I did not defend a dimensional system. Dimensions are no more than collections of psychopathological symptoms with a certain resemblance, and often occurring together. A dimensional approach will not make diagnosis in psychiatry more detailed, more precise, or more scientific.
I did propose a functional system: the development of a diagnostic system based on the psychic dysfunctions underlying psychopathological symptoms. Psychopathological symptoms and psychic dysfunctions are not equivalent concepts. Psychopathological symptoms are the products of psychic dysfunctions, the way these functions are being experienced by the patients, and observed by the investigator. 1 Functionally based diagnosing in psychiatry would imply the development of psychotropic drugs focused on psychic dysfunctions, rather than on man-made nosological constructs or vaguely defined syndromes or dimensions. In this way polypharmacy would become a scientifically based therapeutic approach.
